We invite you again this year to participate in an interactive exchange of information on the extended use of known markers and new procedures in the field of gastrointestinal tumors.
The medical progress in oncology is rapidly evolving. With the therapeutic expansion through targeted medicine, immune oncology has also seen an improvement in the treatment of these tumor diseases in recent years. In addition to therapeutic progress, the possibilities in diagnostics have also made great strides. Thus, in addition to the known predictive and prognostic markers, new procedures such as NGS analysis or methods for measuring «tumor burden» or ctDNA are no longer used solely for scientific purposes.
With kind regards,
Dr. med. A. Siebenhüner
Prof. Dr. med. Dr. phil. A. Wicki
Klinik für Medizinische Onkologie und Hämatologie (MOH)
PD Dr. med. univ. T. Winder
Swiss Tumor Molecular Institute
Dr. med. S. De Dosso
Oncology Institute of Southern Switzerland, Bellinzona